Genomma Lab Internacional stock

LAB/B · BMV · MXN

Compare Genomma Lab Internacional
$14.48Change from previous close: −1.36%Absolute change: −$0.20

Close · November 20, 2026

Price history

−17.68% over the period

1 year: from $17.59 (November 20, 2025) to $14.48 (November 20, 2026), −17.68%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026$14.48
October 30, 2026$15.17
September 30, 2026$12.51
August 31, 2026$13.17
July 31, 2026$14.67
June 30, 2026$14.98
May 29, 2026$15.96
April 30, 2026$16.43
March 31, 2026$18.16
February 27, 2026$18.28
January 30, 2026$16.63
December 31, 2025$17.91
November 28, 2025$18.74
November 20, 2025$17.59

At a glance

  • The company

    Develops, sells and markets branded pharmaceutical and personal care products including anti-acne, antibacterial, haircare, pain relief and digestive health products

  • Latest results

    Quarter to September 30, 2026 · EPS $0.51 (estimate $0.46)

TickerLandia's take on Genomma Lab Internacional

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$12.22
52-wk high$19.48

−25.67% from the 52-week high

Analysts · 6 analysts

Average target$21.33+47.33% vs. price

Buy 4 · Hold 2 · Sell 0

TickerLandia Fingerprint: Genomma Lab Internacional

Compared with similar companies: very low price and very low growth.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 317 Latin American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Genomma Lab Internacional is cheaper than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), Genomma Lab Internacional's P/E today is 8.76, below the median of its last 9 fiscal years (12.5; between 10.8 and 25.1 from 2017 to 2025). Genomma Lab Internacional's P/E (trailing 12 months): 8.71, −50% against the median of a group of 9 similar companies (17.3).

P/E compared with its history

Compared with 9 similar companies

Genomma Lab Internacional's metrics compared with similar companies
MetricGenomma Lab InternacionalPosition in the groupBand
P/E (trailing 12 months)8.71Low
Forward P/E7.67Low
Operating margin20.0%Middle
ROE14.7%Middle
Debt/equity0.66Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Genomma Lab Internacional. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$4.5B

Latest quarter · Q3 2026

Net income

$514.93M

Latest quarter · Q3 2026

Quarterly net margin

11.4%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$14.81B
P/E
8.7
EPS
$1.74
Volume
3.5M
Daily trading
€2.95M
Dividend yield
5.52%
Last ex-dividend on September 29, 2026

How Genomma Lab Internacional is changing

All results
  • Revenue grew 4.8% a year on average over the last 5 years

  • Operating margin rose from 19.3% to 21.5%

  • Profits turn into cash: free cash flow equal to 152% of net income

Returns

Genomma Lab Internacional returns with dividends

$1,000 invested in Genomma Lab Internacional 5 years ago, on November 22, 2021, would be worth $1,037 today with dividends reinvested: +3.73% in total, +0.74% per year. On price alone it would be $793 (−20.74%).

PeriodGenomma Lab Internacional$1,000 becomes
1 month+1.69%$1,017
6 months−9.05%$910
Year to date−19.15%$808
1 year−13.33%$867
3 years+14.29%$1,143
5 years+3.73%$1,037
10 years−38.28%$617

From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment

The chart in detail

Genomma Lab Internacional: technical analysis

Genomma Lab Internacional shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 63.3% below its all-time closing high ($39.50, December 5, 2013).

Trend
No clear trend
RSI (14 sessions)
46
Between 30 and 70
vs 200-session average
−6.01%

Support and resistance

Price areas where Genomma Lab Internacional has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$16.11+11.23%3 touches, last on November 9, 2026
  2. Resistance$15.78+8.98%3 touches, last on October 27, 2026
  3. Resistance$15.43+6.53%2 touches, last on July 10, 2026
  4. Last price$14.48
  5. Support$13.80−4.73%2 touches, last on August 26, 2026
  6. Support$13.15−9.19%2 touches, last on September 29, 2026
  7. Support$12.30−15.09%2 touches, last on September 30, 2026

Volatility and risk

Volatility (60 sessions, annualised)
32.4%
Largest fall in the last year
−36.17%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Genomma Lab Internacional: seasonality

Average monthly price change over 19 years

+1.6%Jan−4.4%Feb+1.9%Mar+4.7%Apr+1.8%May−0.6%Jun+1.8%Jul+1.0%Aug−2.7%Sep+4.7%Oct−0.4%Nov+0.3%Dec

Over the last 19 years, the strongest month for Genomma Lab Internacional has been April: +4.72% on average, positive in 9 years out of 18. The weakest has been February: −4.43% on average, positive in 4 years out of 18. November, the current month, has been positive in 10 years out of 18 (−0.37% on average).

Show chart data
MonthAverageMedianPositive years
January+1.57%+3.35%10 of 18
February−4.43%−5.87%4 of 18
March+1.89%−1.40%7 of 18
April+4.72%+0.82%9 of 18
May+1.80%+0.14%9 of 18
June−0.60%−0.96%7 of 18
July+1.79%+0.34%11 of 19
August+0.97%−1.30%7 of 19
September−2.67%−3.89%6 of 19
October+4.70%+5.33%13 of 19
November−0.37%+1.36%10 of 18
December+0.26%−2.57%7 of 18

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Genomma Lab Internacional and its competitors

Revenue of 17.5 billion Mexican pesos and a workforce of 1,801 people frame a company that develops, sells and markets pharmaceutical and personal care products, mainly in Mexico and in other countries through the company and its subsidiaries. Its branded range covers anti-acne, anti-fungal and hair-loss products, treatments for muscle pain, hemorrhoids, varicose veins and osteoarthritis, antacids and anti-ulcer medicines, as well as shampoos, soaps, razors and infant nutrition.

Headquarters
Mexico City, Mexico
Employees
1,801
Founded
1996
Chief executive
Juan Marco Sparvieri
Genomma Lab Internacional and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Genomma Lab InternacionalLAB/B$776.89M20.0%8.71−9.05%
HyperaHYPE3$2.58B28.1%8.09−3.50%
PharmaNutraPHN$917.61M22.0%36.7−2.50%
EvotecEVT$489.39M-18.0%—−48.86%
Faes FarmaFAE$1.65B13.0%17.9+4.66%
FagronFAGR$1.97B14.3%19.5−0.20%

Same industry or related industries, similar size. Compare Genomma Lab Internacional with its competitors · Full profile